Millions of ilegal medicines stopped by "MEDI-FAKE" EU customs action

22 December 2008

The European Commission has announced the results of the "MEDI-FAKE" action, which targeted customs control on illegal medicines entering the European Union. On the basis of a risk profile disseminated by the Commission, customs from the 27 member states put special focus over a two-month period on coordinated action to stop illegal medicines from entering the EU. Among the products which were intercepted were antibiotics, anti-cancer, anti-malaria and anti-cholesterol drugs, as well as painkillers, Viagra (sildenafil) and drug precursors.

Laszlo Kovacs, Commissioner for Taxation and Customs, said: "in a two month period, Customs seized more than 34 million illegal pills, far exceeding expectations. This success shows the value of the new Community approach to risk management. It multiplies the effectiveness of customs controls, thereby better protecting citizens and legitimate business from new and increasing security and safety threats. Cooperation between customs and legitimate business proved vital."

Community risk profile applied throughout EU

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight